M&A Deal Summary |
|
|---|---|
| Date | 2022-02-25 |
| Target | Channel Biosciences |
| Sector | Life Science |
| Buyer(s) | Biohaven Pharmaceutical Holding |
| Sellers(s) | Knopp Biosciences |
| Deal Type | Divestiture |
| Deal Value | 100M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2013 |
| Sector | Life Science |
| Employees | 928 |
| Revenue | 463M USD (2021) |
Biohaven Pharmaceutical Holding is a biopharmaceutical company engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. Biohaven Pharmaceutical Holding was incorporated in 2013 and is based in New Haven, Connecticut.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Pennsylvania M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2022 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
Knopp Biosciences is a drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet needs. Knopp's clinical-stage oral small molecule, dexpramipexole, is in development for eosinophilic asthma. Knopp Biosciences is based in Pittsburgh, Pennsylvania.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Pennsylvania M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2022 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
